Mirati Therapeutics, Inc. (MRTX) financial statements (2021 and earlier)

Company profile

Business Address 9393 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments415223151571222962
Cash and cash equivalents47331082249714
Short-term investments3691904334732348
Prepaid expense6132221
Income taxes receivable0
Other current assets222111 
Other undisclosed current assets2100011
Total current assets:424227156601253364
Noncurrent Assets
Property, plant and equipment2011100
Other noncurrent assets611320 
Total noncurrent assets:8214310
TOTAL ASSETS:432228157631283365
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:482614151055
Accounts payable16946221
Accrued liabilities211066522
Employee-related liabilities8633212
Other undisclosed accounts payable and accrued liabilities31000  
Deferred revenue1
Derivative instruments and hedges, liabilities      33
Contract with customer, liability0
Total current liabilities:4926141510539
Noncurrent Liabilities
Liabilities, other than long-term debt110000 
Accounts payable and accrued liabilities11     
Other liabilities  0000 
Total noncurrent liabilities:110000 
Total liabilities:5027141510539
Stockholders' equity
Stockholders' equity attributable to parent382202143481182826
Common stock0000000
Additional paid in capital1,145751594429415261215
Accumulated other comprehensive income109910101010
Accumulated deficit(772)(559)(461)(390)(307)(242)(198)
Total stockholders' equity:382202143481182826
TOTAL LIABILITIES AND EQUITY:432228157631283365

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:313     
Operating expenses(225)(116)(72)(84)(65)(39)(32)
Operating loss:(222)(103)(72)(84)(65)(39)(32)
Nonoperating income (expense)126110(0)(2)
Investment income, nonoperating310  (1) 
Foreign currency transaction gain (loss), before tax     0(1)
Other nonoperating income (expense)94110(0)(1)
Loss from continuing operations before equity method investments, income taxes:(210)(97)(70)(83)(65)(40)(34)
Other undisclosed loss from continuing operations before income taxes(3)(1)(0)  (4)(18)
Loss from continuing operations before income taxes:(213)(98)(70)(83)(65)(44)(53)
Income tax benefit      0
Net loss available to common stockholders, diluted:(213)(98)(70)(83)(65)(44)(53)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(213)(98)(70)(83)(65)(44)(53)
Comprehensive loss:(213)(98)(70)(83)(65)(44)(53)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0 (0)(0)00(0)
Comprehensive loss, net of tax, attributable to parent:(213)(98)(70)(83)(65)(44)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: